Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ImmutepSTU:YP1A -6.72%30 EV-to-EBIT is 0.11 as of Sep. 22, 2026. GuruFocus rates STU:YP1A with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 381 Biotechnology companies, Immutep ranks better than 91.34% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Immutep's Enterprise Value is €-5.09 Mil.
Immutep's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was €-45.91 Mil. Therefore, Immutep's EV-to-EBIT for today is 0.11.
The historical rank and industry rank for Immutep's EV-to-EBIT or its related term are showing as below:
STU:YP1A'
s EV-to-EBIT Range Over the Past 10 Years
Min: -0.19 Med: 0 Max: 0.27
Current: 0.27
During the past 13 years, the highest EV-to-EBIT of Immutep was 0.27. The lowest was -0.19. And the median was 0.00.
STU:YP1A's EV-to-EBIT is ranked better than 91.34% of 381
companies
in the Biotechnology industry
Industry Median: 14.08
vs STU:YP1A: 0.27
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Immutep's Enterprise Value for the quarter that ended in Jun. 2026 was €12.64 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Immutep's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was €-45.91 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immutep EV-to-EBIT Related Terms
Immutep EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Immutep's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:YP1A vs VRTX, REGN, MRNA: EV-to-EBIT Comparison
For the Biotechnology subindustry, Immutep's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immutep EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immutep's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Immutep's EV-to-EBIT falls into.
Immutep's current Enterprise Value is €-5.09 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Immutep's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was €-45.91 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immutep (STU:YP1A) has a EV-to-EBIT of 0.11 as of Sep. 22, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Immutep and its competitors. According to the industry distribution chart, Immutep ranks #33 out of 381 companies in the Biotechnology industry, placing it in the top 8.7%.
Is Immutep's EV-to-EBIT too high?
Immutep's current EV-to-EBIT is 0.11. The Biotechnology industry median EV-to-EBIT is 14.08. Immutep's value of 0.11 is 99.2% below this industry median. Based on the distribution chart, Immutep ranks #33 out of 381 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Immutep has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Immutep's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Immutep ranks #33 out of 381 companies for EV-to-EBIT. This places Immutep in the top 9% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 14.08. Immutep's value of 0.11 is 99.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 14.08, based on 381 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Immutep's current EV-to-EBIT of 0.11 is 99.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Immutep and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 14.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Immutep's current EV-to-EBIT is 0.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immutep stock overvalued right now?
Immutep (STU:YP1A) has a current EV-to-EBIT of 0.11. The current EV-to-EBIT is 0.11 and 99.2% below the Biotechnology industry median of 14.08. Immutep's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Immutep (STU:YP1A), the current EV-to-EBIT is 0.11 as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
30GF Score
Get the complete analysis for STU:YP1A
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:YP1A has been successfully added to your 
